 Tinzaparin sodium is superior to UFH in terms of reducing cardio-vascular and cerebrovascular outcomes primary end-point. Tinzaparin sodium is superior to UFH in terms of reducing the specified lipid parameters of stable diabetic patients on chronic hemodialysis. 